COVID-19 survivors and kidney disease: The long term effects on kidney function, and health outcomes for people with pre-existing chronic kidney disease - a study using electronic health records

  • Funded by Department of Health and Social Care / National Institute for Health and Care Research (DHSC-NIHR)
  • Total publications:27 publications

Grant number: NIHR301535

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2021
    2024
  • Known Financial Commitments (USD)

    $689,641.2
  • Funder

    Department of Health and Social Care / National Institute for Health and Care Research (DHSC-NIHR)
  • Principal Investigator

    N/A

  • Research Location

    United Kingdom
  • Lead Research Institution

    London School of Hygiene and Tropical Medicine
  • Research Priority Alignment

    N/A
  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Post acute and long term health consequences

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

Aims of my research I aim to investigate whether people who survive COVID-19 are more likely to lose kidney function, partially or completely; I also aim to build and test a prediction tool to work out which survivors are most likely to be at longer-term risk of serious declines in kidney function. I will also be investigating the impact of COVID-19 on survivors who had kidney disease before they became unwell, and whether this increases risk of experiencing bad outcomes earlier, such as death, complete kidney failure, heart attacks, and frailty. Background When people are admitted to hospital with COVID-19, one of the common consequences is kidney injury. We are not certain why, or whether this has long-term effects in survivors, but there are strong reasons to be concerned that it may. Long-term kidney damage, known as chronic kidney disease (CKD), is associated with earlier death and heart attacks. When CKD leads to kidney failure, people require dialysis or a kidney transplant to stay alive. This has a big impact on quality and length of life, and comes at great cost to the NHS. Therefore, we need to find out what the long-term risks of COVID-19 are to kidney function, and determine who is at the greatest risk so they can be closely monitored and treated. Design and methods A way of addressing important health concerns relatively quickly is by analysing health records which cover millions of people. In the UK, we have electronically coded GP records, and for most people, we can combine these with records from hospitals. I will use these anonymised records for two study populations: Study A: I will compare risks of change in kidney function or complete kidney failure between COVID-19 survivors and people of the same age, sex, and under the same GP. Study B: Among people with pre-existing CKD, I will compare risks of death, hospital admissions, complete kidney failure, heart attacks, blood clots, low red blood cell levels, and frailty between COVID-19 survivors to people who are the same age, sex, and have the same level of pre-existing CKD. I will replicate my work with records from Sweden to understand if the findings are specific to COVID-19 or influenced by factors such as health-care system and the characteristics of the local population. I will account for many other factors like age, ethnicity, socio-economic status and pre-existing medical problems like diabetes, to establish whether our results are likely to be due to COVID-19 itself, or were due to differences in who developed severe infection. I will apply statistical modelling to records from Study A to create a straightforward tool using information like routine test results or medical history, to predict which patients are most at risk of kidney failure. I will then test this model on another large set of records from the UK and from Sweden to ensure that it is reliable. Patient and public involvement My ideas have been informed by meetings including patients, and several patients are keen to join my advisory panel. I will ensure this includes COVID-19 survivors with and without CKD, and a member of public who has not had COVID-19. We will meet at the start of my research to finalise plans, and then I will update them of my progress every six months. I will seek their advice on how to ensure my findings reach other patients and the public. Dissemination Because this is a big, important study, I will share findings with the media, charities, healthcare professionals, and policy makers to ensure that it has maximum benefit for patients.

Publicationslinked via Europe PMC

Last Updated:41 minutes ago

View all publications at Europe PMC

Kidney Function Decline After COVID-19 Infection.

Drug use and acute kidney injury: a Drug-Wide Association Study (DWAS) in Denmark and Sweden.

Ursodeoxycholic acid and severe COVID-19 outcomes in a cohort study using the OpenSAFELY platform.

Impacts of the COVID-19 pandemic on deprivation-level differences in cardiovascular hospitalisations: a comparison of England and Denmark using the OpenSAFELY platform and National Registry Data.

Incidence of diabetes after SARS-CoV-2 infection in England and the implications of COVID-19 vaccination: a retrospective cohort study of 16 million people.

Impact of COVID-19 on recorded blood pressure screening and hypertension management in England: an analysis of monthly changes in the quality and outcomes framework indicators in OpenSAFELY.

Clinical coding of long COVID in primary care 2020-2023 in a cohort of 19 million adults: an OpenSAFELY analysis.

Impact of long COVID on health-related quality-of-life: an OpenSAFELY population cohort study using patient-reported outcome measures (OpenPROMPT).

Identification of patients undergoing chronic kidney replacement therapy in primary and secondary care data: validation study based on OpenSAFELY and UK Renal Registry.